Several studies revealed that lack of MLH1 and MSH2 could induce cisplatin resistance in tumor cells, whereas low expression levels of MLH1 and MSH2 resulted in poor survival in ovarian and bladder cancer patients treated whit platinum drugs (36-38). Here, MLH1 is linked to urinary bladder carcinoma.